Drug: GC4419
GTI-4419-202
Phase 2 small_molecule completed
Quick answer
Drug: GC4419 for Head and Neck Cancer is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Galera Therapeutics
- Indication
- Head and Neck Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed